Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06726590 · ClinicalTrials.gov registry record
Interprofessional Pharmacogenomics (IPGx) Registry and Repository
A clinical trial of Cancer and Diabetes, sponsored by Texas A&M University.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT06726590: Recruiting study of Cancer and Diabetes, sponsored by Texas A&M University.
NCT06726590 is a study of Cancer and Diabetes that is actively recruiting participants, run by Texas A&M University. The registered enrollment target is 3,000 participants, below the 3,486-participant average among 615 other Cancer trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06726590, a study of Cancer and Diabetes, is actively recruiting participants, sponsored by Texas A&M University.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This program collects genetic and health information to help doctors choose the right medications for patients.
Primary Outcome
Patients will be referred to the Texas A\&M Interprofessional Pharmacogenomics Clinic (IPGx) by their primary care physicians. A physician or ambulatory pharmacist in the IPGx clinic or Family Care Clinic will obtain a complete medical history, physical examination, and validate the patient's current concomitant medication list at the IPGx during the office visit. Patient medical information would be input into the CSN, which functions as a computable EHR medical record analysis, evaluation of p
Conditions Studied
Study Locations (1)
Texas
- Texas A&M Family Care - Bryan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2025-11 |
| Est. Completion | 2029-11 |
What NCT06726590 shows while recruiting
NCT06726590 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,486-participant average among 615 other Cancer trials with a reported enrollment target (14% lower).
The record links to 9 conditions, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06726590 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06726590 about?
NCT06726590 is a clinical study titled "Interprofessional Pharmacogenomics (IPGx) Registry and Repository". This program collects genetic and health information to help doctors choose the right medications for patients.
What is the current status of trial NCT06726590?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2025-11. Estimated completion is 2029-11.
What conditions does trial NCT06726590 study?
This clinical trial studies the following conditions: Cancer, Diabetes, COPD, Heart Disease, Polypharmacy.
Who is sponsoring clinical trial NCT06726590?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06726590 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06726590's enrollment target sits among peer trials
3,000 50th of 615 higher than 565 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia